A Study to Learn About the Study Medicine (CIBINQO) in People With Atopic Dermatitis.
Launched by PFIZER · May 19, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a medication called CIBINQO to see how safe and effective it is for treating atopic dermatitis, a skin condition that causes itchy and inflamed skin. The trial is currently looking for participants, and anyone aged 4 to 82 who is either starting this treatment for the first time or continuing it after being transferred from another hospital may be eligible to join. However, individuals who have previously participated in this study at the same location cannot enroll again.
If you decide to participate, you can expect to receive the study medication and be monitored closely by the researchers to help determine how well it works and if there are any side effects. This is an important step in understanding how CIBINQO can help people with atopic dermatitis, and your involvement could contribute valuable information to improve treatment options for this condition.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. Participants receiving this Product for treatment of AD.
- • 2. Participants start receiving this Product (commercial product) for the first time and no earlier than the contract date of this Study, or Participants who continues to receive this drug after hospital transfer can be registered retrospectively.
- Exclusion Criteria:
- • 1. Participants previously enrolled in this Study at the same site.
About Pfizer
Pfizer Inc. is a global leader in biopharmaceutical innovation, dedicated to discovering, developing, and delivering advanced therapies that enhance patient outcomes across a wide range of medical conditions. With a rich history of scientific research and a commitment to quality, Pfizer focuses on areas such as oncology, immunology, cardiology, and rare diseases. The company leverages cutting-edge technology and collaborates with healthcare professionals, regulatory bodies, and academic institutions to conduct rigorous clinical trials that ensure the safety and efficacy of its products. Pfizer's mission is to bring breakthroughs that change patients' lives, exemplifying its commitment to health and wellness worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tokyo, , Japan
Patients applied
Trial Officials
Pfizer CT.gov Call Center
Study Director
Pfizer
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials